TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19459424

Group type: EXPERIMENTAL
Intervention: Ingavirin (90 mg once daily for 5 days)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Arbidol (200 mg 4 times a day for 5 days)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 17083396

Group type: EXPERIMENTAL
Intervention: Laparoscopic orchiopexy
Number of subjects: 82

Group type: COMPARATOR
Intervention: Open orchiopexy
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Laparoscopic second stage Fowler‐Stephens orchiopexy
Number of subjects: 82

Group type: COMPARATOR
Intervention: Open second stage Fowler‐Stephens orchiopexy
Number of subjects: 82
Study: 14713135

Group type: EXPERIMENTAL
Intervention: Desipramine (150 mg/d) plus contingency management
Number of subjects: 151

Group type: COMPARATOR
Intervention: Desipramine (150 mg/d) plus noncontingent voucher control
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo plus contingency management
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo plus noncontingent voucher control
Number of subjects: 151
Study: 10890475

Group type: EXPERIMENTAL
Intervention: Hemofiltration with half‐Hammersmith dosing regimen of aprotinin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hemofiltration with full‐Hammersmith dosing regimen of aprotinin
Number of subjects: 0

Group type: COMPARATOR
Intervention: No hemofiltration with half‐Hammersmith dosing regimen of aprotinin
Number of subjects: 0

Group type: COMPARATOR
Intervention: No hemofiltration with full‐Hammersmith dosing regimen of aprotinin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hemofiltration
Number of subjects: 0

Group type: COMPARATOR
Intervention: No hemofiltration
Number of subjects: 0
Study: 8851621

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1,000 mg intravenously 30 min before anesthesia (group 1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1,000 mg intravenously followed by a second 1,000 mg at initiation of cardiopulmonary bypass (group 2)
Number of subjects: 20
Study: 1620414

Group type: EXPERIMENTAL
Intervention: Oxycodone 10 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Paracetamol 1000 mg
Number of subjects: 20
Study: 6422868

Group type: EXPERIMENTAL
Intervention: Branched chain enriched therapy at 0.7 gm/kg/day of branched chain amino acids
Number of subjects: 23

Group type: COMPARATOR
Intervention: Balanced parenteral nutrition with 1.5 gm/kg/day of amino acids, 30 calories/kg/day of glucose, and 7 calories/kg/day of fat
Number of subjects: 23
Study: 30944164

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (continuing)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (in vitro)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Cotrimoxazole (stopping)
Number of subjects: 293
Study: 30708068

Group type: EXPERIMENTAL
Intervention: Reproductive health knowledge score based on a questionnaire with 28 items
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Age of participants
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Fathers' education level
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Perception of violence
Number of subjects: 412
Study: 28818422

Group type: EXPERIMENTAL
Intervention: Exercise intervention group (EX)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 42
Study: 25986030

Group type: EXPERIMENTAL
Intervention: Surgical staging and RCTX (arm A)
Number of subjects: 255

Group type: COMPARATOR
Intervention: RCTX (arm B)
Number of subjects: 255
Study: 24170747

Group type: COMPARATOR
Intervention: Patient self-management (OL)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: International artificial pancreas (iAP)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: University of Cambridge (CAM)
Number of subjects: 48
Study: 21358538

Group type: EXPERIMENTAL
Intervention: Oscillometric device (IG)
Number of subjects: 1832
Study: 20127537

Group type: EXPERIMENTAL
Intervention: 16 mg i.v. Lornoxicam
Number of subjects: 2

Group type: COMPARATOR
Intervention: Saline solution (Control)
Number of subjects: 2
Study: 17174387

Group type: EXPERIMENTAL
Intervention: Intervention group (N=217)
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Intervention group (N=168)
Number of subjects: 555
Study: 15481277

Group type: EXPERIMENTAL
Intervention: Heavy progressive resistance training (RE) twice a week for 12 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Breathing exercises (CON)
Number of subjects: 18
Study: 11966504

Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cisapride
Number of subjects: 28
Study: 9541173

Group type: EXPERIMENTAL
Intervention: Night-time continuous subcutaneous insulin infusion (CSII) therapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Bedtime NPH insulin
Number of subjects: 14
Study: 8291156

Group type: EXPERIMENTAL
Intervention: Partial meniscectomy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Total meniscectomy
Number of subjects: 200
Study: 2656442

Group type: EXPERIMENTAL
Intervention: 3 g piracetam/day i.v. followed by 3 x 800 mg/day p.o. for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo i.v. and then p.o.
Number of subjects: 40
Study: 29548719

Group type: EXPERIMENTAL
Intervention: Dapagliflozin/metformin XR FCDP (10/1000 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Individual component tablets (dapagliflozin [10 mg] plus metformin XR [2 × 500 mg])
Number of subjects: 40
Study: 28895887

Group type: EXPERIMENTAL
Intervention: Daily dose (HD: high dose)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: 5X/week (MD: Moderate Dose)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: 3X/week (LD: Low Dose)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Unfortified (Control)
Number of subjects: 246
Study: 25530347

Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) treatment
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (sensory stimulation without RF lesioning)
Number of subjects: 62
Study: 23479321

Group type: EXPERIMENTAL
Intervention: HIV/tuberculosis subjects with high CD4 T-cell count (≥ 350/μL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV/tuberculosis subjects with low CD4 T-cell count (<350/μL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV/tuberculosis patients with CD4 T-cell count ≥ 350/μL
Number of subjects: 0
Study: 20921029

Group type: EXPERIMENTAL
Intervention: Intermittent high-intensity therapy (Group A): 3 two-month blocks, 4 sessions per week (30-45 minutes each), total 96 sessions
Number of subjects: 50

Group type: COMPARATOR
Intervention: Continuous low-intensity therapy (Group B): 2 sessions per week (30-45 minutes each), total 104 sessions
Number of subjects: 50

Group type: COMPARATOR
Intervention: Group B (Continuous low-intensity therapy)
Number of subjects: 50
Study: 19589952

Group type: EXPERIMENTAL
Intervention: Elevated muscle temperature during cycling at 75% ventilatory threshold
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (normal muscle temperature) during cycling at 75% ventilatory threshold
Number of subjects: 16
Study: 16396977

Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg/day)
Number of subjects: 1346

Group type: EXPERIMENTAL
Intervention: Anakinra (0 to 3 years)
Number of subjects: 1346

Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 1346
Study: 15335093

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate gel
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Neem extract gel
Number of subjects: 48

Group type: COMPARATOR
Intervention: Chlorhexidine gluconate mouthwash
Number of subjects: 48
Study: 11071803

Group type: EXPERIMENTAL
Intervention: High-dose lisinopril (32.5-35 mg/day)
Number of subjects: 3164

Group type: COMPARATOR
Intervention: Low-dose lisinopril (2.5-5 mg/day)
Number of subjects: 3164
Study: 9186877

Group type: EXPERIMENTAL
Intervention: Ritodrine (N = 42)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Terbutaline (N = 41)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Ritodrine or Terbutaline (N = 14)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Saline and Morphine (N = 12)
Number of subjects: 83
Study: 8084977

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lithium (maintenance therapy)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nonpharmacologic approaches (ECT, sleep deprivation, light therapy)
Number of subjects: 100
Study: 7142413

Group type: EXPERIMENTAL
Intervention: CS plus rational self‐statements
Number of subjects: 0

Group type: COMPARATOR
Intervention: CS plus irrational self‐statements
Number of subjects: 0

Group type: COMPARATOR
Intervention: CS alone
Number of subjects: 0
Study: 30910420

Group type: EXPERIMENTAL
Intervention: Combined aerobic exercise and cognitive training (EX/CT) program
Number of subjects: 69

Group type: COMPARATOR
Intervention: Usual care attention control (UCAC) stretching and flexibility program
Number of subjects: 69
Study: 28150513

Group type: EXPERIMENTAL
Intervention: Patients with RA
Number of subjects: 208

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 208
Study: 24968129

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 20-2 ppm for 24 days
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 2 ppm
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (no iNO)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 125
Study: 23705849

Group type: EXPERIMENTAL
Intervention: Collaborative care with duloxetine
Number of subjects: 189

Group type: COMPARATOR
Intervention: Collaborative care with placebo
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Duloxetine alone
Number of subjects: 189
Study: 21714365

Group type: EXPERIMENTAL
Intervention: Needs-oriented discharge planning intervention (manualised, two sessions at discharge and 3 months thereafter)
Number of subjects: 491
Study: 19144162

Group type: EXPERIMENTAL
Intervention: Self-help online
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapy online
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 0
Study: 17699475

Group type: EXPERIMENTAL
Intervention: Ruboxistaurin (RBX)
Number of subjects: 1157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1157
Study: 16520559

Group type: EXPERIMENTAL
Intervention: Exercise program (12 weeks, 60 minutes per session, 5 times per week)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study: 12930486

Group type: EXPERIMENTAL
Intervention: Anxiety-blocker (placebo purported to block anxiety)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Memory-enhancer (placebo purported to enhance memory)
Number of subjects: 0
Study: 10323447

Group type: EXPERIMENTAL
Intervention: DMARD + prednisolone
Number of subjects: 26

Group type: COMPARATOR
Intervention: DMARD alone
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 26
Study: 8984133

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once a day
Number of subjects: 407

Group type: COMPARATOR
Intervention: Enalapril 20 mg once a day
Number of subjects: 407
Study: 1665179

Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg and Hydrochlorothiazide 12.5 mg once daily (L/HCTZ)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Captopril 25 mg and Hydrochlorothiazide 25 mg once daily (C/HCTZ)
Number of subjects: 165
Study: 7099904

Group type: EXPERIMENTAL
Intervention: 30 min. of steady-state treadmill running
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 20 min. of treadmill running followed by progressively increasing speed until exhaustion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control
Number of subjects: 18
Study: 29915931

Group type: EXPERIMENTAL
Intervention: Tuberosity grafts (TG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lateral palate grafts (PG)
Number of subjects: 20
Study: 28689046

Group type: EXPERIMENTAL
Intervention: LUCAS mechanical chest compression
Number of subjects: 1035

Group type: COMPARATOR
Intervention: Manual chest compression
Number of subjects: 1035
Study: 26106632

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam‐ketamine
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam‐fentanyl
Number of subjects: 38
Study: 23060628

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 22340165

Group type: EXPERIMENTAL
Intervention: Electrocautery hook
Number of subjects: 120

Group type: COMPARATOR
Intervention: Titanium clip
Number of subjects: 120
Study: 19144212

Group type: EXPERIMENTAL
Intervention: Long-term use of rivastigmine
Number of subjects: 29
Study: 16239239

Group type: EXPERIMENTAL
Intervention: Hospital in the Home (early discharge)
Number of subjects: 104
Study: 12972723

Group type: EXPERIMENTAL
Intervention: semi-standardized acupuncture (150 patients)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: minimal acupuncture at non-acupuncture points (75 patients)
Number of subjects: 300

Group type: COMPARATOR
Intervention: no treatment for two months followed by semi-standardized acupuncture (75 patients, waiting list control)
Number of subjects: 300
Study: 10755576

Group type: EXPERIMENTAL
Intervention: rhGH (0.05 mg/kg subcutaneously)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 8757210

Group type: EXPERIMENTAL
Intervention: Low-allergen gloves
Number of subjects: 52

Group type: COMPARATOR
Intervention: High-allergen gloves
Number of subjects: 52

Group type: COMPARATOR
Intervention: Nonsurgery days
Number of subjects: 52
Study: 1358235

Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine q.d.s.
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 6443576

Group type: EXPERIMENTAL
Intervention: Orchiectomy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Chronic administration of an LHRH agonistic analogue by parenteral and/or intranasal routes
Number of subjects: 29
Study: 30341003

Group type: EXPERIMENTAL
Intervention: High-dose oxytocin (6.6 mU/minute)
Number of subjects: 1351

Group type: COMPARATOR
Intervention: Low-dose oxytocin (3.3 mU/minute)
Number of subjects: 1351
Study: 29408705

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HyperBOT) at 2.5 ATA for 60 minutes
Number of subjects: 79

Group type: COMPARATOR
Intervention: Normobaric oxygen therapy (NormBOT) at 1.5 ATA
Number of subjects: 79
Study: 26597468

Group type: EXPERIMENTAL
Intervention: Combined cervical plexus block (deep plus superficial)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Intermediate cervical plexus block
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combined cervical plexus block
Number of subjects: 48
Study: 24593826

Group type: EXPERIMENTAL
Intervention: rhBNP in high BNP group (n = 28)
Number of subjects: 105

Group type: COMPARATOR
Intervention: dobutamine in high BNP group (n = 30)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: rhBNP in extra-high BNP group (n = 24)
Number of subjects: 105

Group type: COMPARATOR
Intervention: dobutamine in extra-high BNP group (n = 23)
Number of subjects: 105
Study: 22891214

Group type: EXPERIMENTAL
Intervention: Recovery with hyperglycemia after hypoglycemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recovery with normoglycemia after hypoglycemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recovery with hyperglycemia after hypoglycemia with vitamin C infusion
Number of subjects: 0
Study: 21152391

Group type: EXPERIMENTAL
Intervention: Increased activity in the fusiform gyrus (FG) correlated with trait anxiety and negatively correlated with WM performance.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decreased activity in the right lateral prefrontal cortex (PFC) negatively correlated with trait anxiety.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Engagement of medial and left lateral PFC in coping with distraction.
Number of subjects: 0
Study: 17632038

Group type: EXPERIMENTAL
Intervention: Exposure in vivo aimed to systematically reduce the perceived harmfulness of activities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Graded activity that did not address assumptions about harmfulness
Number of subjects: 0
Study: 16376646

Group type: EXPERIMENTAL
Intervention: Direct plating onto standard media
Number of subjects: 100

Group type: COMPARATOR
Intervention: Amies transport medium after 4 hours
Number of subjects: 100

Group type: COMPARATOR
Intervention: Amies transport medium after 24 hours
Number of subjects: 100

Group type: COMPARATOR
Intervention: Amies transport medium for cases that did not yield organisms by direct plating
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparison of recovery rates
Number of subjects: 100
Study: 11172843

Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRH‐a) plus tibolone (2.5 mg/d orally)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRH‐a) plus tibolone
Number of subjects: 30

Group type: COMPARATOR
Intervention: GnRH agonist (GnRH‐a) plus placebo (1 tablet per day orally)
Number of subjects: 30
Study: 9625399

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral alcohol reduction intervention program
Number of subjects: 641

Group type: COMPARATOR
Intervention: Control observation group
Number of subjects: 641
Study: 8169458

Group type: EXPERIMENTAL
Intervention: Subcutaneous 200-ng bolus of octreotide
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 3277484

Group type: EXPERIMENTAL
Intervention: Oximeter data available to anesthesia team
Number of subjects: 152

Group type: COMPARATOR
Intervention: Oximeter data unavailable to anesthesia team
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: ASA Physical Status 3 and 4 patients
Number of subjects: 152
Study: 31566888

Group type: EXPERIMENTAL
Intervention: Virtual task (Kinect, no physical contact)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Real task (Keyboard, with physical contact)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Virtual training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-touch task (virtual environment)
Number of subjects: 50
Study: 28536184

Group type: EXPERIMENTAL
Intervention: 30 g casein protein with 2 g free leucine (PRO+leu)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 30 g casein protein without 2 g free leucine (PRO)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Noncaloric placebo (PLA)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Protein ingestion before sleep
Number of subjects: 36
Study: 27837162

Group type: EXPERIMENTAL
Intervention: Closed-loop (CL) on day 1 of sensor insertion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Closed-loop (CL) on day 3-4 after sensor insertion
Number of subjects: 12
Study: 26590903

Group type: EXPERIMENTAL
Intervention: Home enteral nutrition through a jejunostomy for six weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 54
Study: 24285757

Group type: EXPERIMENTAL
Intervention: Alvimopan (with preoperative dose)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Alvimopan (without preoperative dose)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no alvimopan)
Number of subjects: 50
Study: 21263080

Group type: EXPERIMENTAL
Intervention: WL + PA
Number of subjects: 0

Group type: COMPARATOR
Intervention: PA
Number of subjects: 0

Group type: COMPARATOR
Intervention: SA
Number of subjects: 0
Study: 18932221

Group type: EXPERIMENTAL
Intervention: Sapropterin dihydrochloride (5, 10, or 20 mg/kg/day)
Number of subjects: 80
Study: 17147074

Group type: EXPERIMENTAL
Intervention: Continuous ultrasound (US)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (sham-US)
Number of subjects: 58
Study: 12669757

Group type: EXPERIMENTAL
Intervention: Preview benefit with occluded old items
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preview benefit with non-occluded old items
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Movement of irrelevant stimuli
Number of subjects: 0
Study: 10235195

Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg nocte
Number of subjects: 35

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 35
Study: 8907720

Group type: EXPERIMENTAL
Intervention: Nefazodone (NEF) 200 mg under fasting conditions
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nefazodone (NEF) 200 mg after a high‐fat breakfast
Number of subjects: 24
Study: 1875712

Group type: EXPERIMENTAL
Intervention: 0.5 g ethanol/kg body weight
Number of subjects: 8

Group type: COMPARATOR
Intervention: Iso-volumic control drink
Number of subjects: 8
Study: 6198807

Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Anti-oxidants (tocopherol, glutathione, cysteamine, cysteine)
Number of subjects: 100
Study: 31683350

Group type: EXPERIMENTAL
Intervention: Subvastus approach (group S)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Parapatellar approach (control group P)
Number of subjects: 93
Study: 29741913

Group type: EXPERIMENTAL
Intervention: Sparse representation‐based variable selection (SRVS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ANOVA-based gene selection approaches
Number of subjects: 0
Study: 27523782

Group type: EXPERIMENTAL
Intervention: Cooking classes focusing on salt reduction
Number of subjects: 68

Group type: COMPARATOR
Intervention: Lectures about a healthy lifestyle
Number of subjects: 68
Study: 24603072

Group type: EXPERIMENTAL
Intervention: 0.9 mg/kg r‐tPA
Number of subjects: 3035

Group type: COMPARATOR
Intervention: Control
Number of subjects: 3035
Study: 21475963

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG IUS)
Number of subjects: 230
Study: 21197501

Group type: EXPERIMENTAL
Intervention: Immediate loading of single implants placed in extraction sockets
Number of subjects: 139

Group type: COMPARATOR
Intervention: Immediate loading of single implants placed in healed ridges
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Immediate implants (both groups)
Number of subjects: 139
Study: 18450623

Group type: EXPERIMENTAL
Intervention: Mini-midvastus approach (group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard approach (group B)
Number of subjects: 100
Study: 15877991

Group type: EXPERIMENTAL
Intervention: Intensified support to quit smoking and dietary modification
Number of subjects: 172

Group type: COMPARATOR
Intervention: General lifestyle advice (Control)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Smoking cessation (in intervention group)
Number of subjects: 172